Avidity Biosciences, Inc. Common Stock (RNAM) Stock Price

RNAMStock
$0.00
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta—

RNAM Share Price Chart

Favorite Metrics

VGM Score85.62

RNAM Analyst Recommendations

Nov 2025
Dec 2025
Jan 2026
Feb 2026
3.76
3.50
3.50
3.50

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
RNAMAvidity Biosciences, Inc. Common Stock
—A—541.4x106.3%——$0.00
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Avidity Biosciences, Inc. Common Stock

Avidity Biosciences is a biopharmaceutical company developing a novel class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company has three programs in registrational clinical trials: Del-desiran for myotonic dystrophy type 1, Del-zota for Duchenne muscular dystrophy, and Del-brax for facioscapulohumeral muscular dystrophy.